Corrigendum to An overview of the safety pharmacology society strategic plan [Journal of Pharmacological and Toxicological Methods 93 (2018) 35-45]
J Pharmacol Toxicol Methods
.
2019 Jan-Feb:95:1.
doi: 10.1016/j.vascn.2018.09.003.
Epub 2018 Nov 3.
Authors
M K Pugsley
1
,
S Authier
2
,
J E Koerner
3
,
W S Redfern
4
,
C G Markgraf
5
,
T Brabham
6
,
K Correll
7
,
M V Soloviev
8
,
A Botchway
9
,
M Engwall
10
,
M Traebert
11
,
J-P Valentin
12
,
T J Mow
13
,
A Greiter-Wilke
14
,
D J Leishman
15
,
H M Vargas
10
Affiliations
1
Purdue Pharma L.P., Stamford, CT 06901, USA. Electronic address:
[email protected]
.
2
CiToxLAB North America, Laval, QC, Canada.
3
U.S. Food & Drug Administration, Silver Spring, MD, USA.
4
Safety & ADME Translational Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
5
Sunovion Pharmaceuticals Inc, Marlborough, MA 01752, USA.
6
Teva Pharmaceuticals, North Wales, PA 19454, USA.
7
Safety Pharmacology Society, Reston, VA 20191, USA.
8
Incyte Corporation, Wilmington, DE 19803, USA.
9
Xenometrics LLC, Stilwell, KS 66085, USA.
10
Amgen Inc., Thousand Oaks, CA 91320, USA.
11
Novartis Pharma AG, Basel, Switzerland.
12
UCB-Biopharma, Belgium.
13
Novo Nordisk, Copenhagen, Denmark.
14
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
15
Eli Lilly, Indianapolis, IN, USA.
PMID:
30399523
DOI:
10.1016/j.vascn.2018.09.003
No abstract available
Publication types
Published Erratum